Table 1 Demographics and pathology results in women with stage IA endometrial cancer

Age(years)

51.89 ± 8.99

56.37 ± 9.19

<0.001

56.07 ± 9.27

60.19 ± 9.71

0.056

BMI>24(kg/m²)

117(30.08%)

37(25.52%)

0.301

27(38.03%)

7(25.93%)

0.280

Arterial hypertension

127(32.65%)

46(31.72%)

0.839

26(36.62%)

9(33.33%)

0.762

Diabetes mellitus

50(12.85%)

22(15.17%)

0.485

11(15.49%)

3(11.11%)

0.571

Menopause

190(48.84%)

93(64.14%)

0.002

50(70.42%)

22(81.48%)

0.268

Nulliparity

26(6.68%)

7(4.83%)

0.428

3(4.22%)

1(3.70%)

0.906

Lymphadenectomy

0.001

0.239

 Sentinel pelvic

43(15.99%)

0(0.00%)

2(3.23%)

0(0.00%)

 Systemic pelvic

58(21.57%)

39(47.56%)

8(12.90%)

13(15.66%)

 Systemic pelvic and para-aortic

168(62.45%)

43(52.44%)

52(83.87%)

70(84.34%)

Radiotherapy

22(5.66%)

5(3.45%)

0.300

11(15.49%)

7(25.93%)

0.246

Chemotherapy

100(25.71%)

17(11.72%)

0.001

51(71.83%)

15(55.56%)

0.125

MI

0.071

0.645

 None

151(38.82%)

44(30.34%)

19(27.76%)

6(22.22%)

 <1/2

238(61.18%)

101(69.66%)

52(73.24%)

21(77.78%)

Grade

0.433

0.400

 G1

173(44.47%)

59(40.69%)

–

–

 G2

216(55.53%)

86(59.31%)

–

–

 G3 Endometrioid

–

–

46(64.79%)

15(55.56%)

 Non-endometrioid

–

–

25(35.21%)

12(44.44%)

Positive LVSI

17(4.37%)

5(3.45%)

0.634

12(16.90%)

4(14.81%)

0.801

Positive peritoneal cytology

55(14.14%)

8(5.52%)

0.006

12(17.65%)

2(7.41%)

0.343

Recurrence

7(1.80%)

0(0.00%)

0.198

9(12.68%)

2(7.41%)

0.443

Death

2(0.51%)

0(0.00%)

>0.99

2(2.82%)

0(0.00%)

>0.99

Length of follow-up (months)

52.88 ± 24.75

83.96 ± 33.95

<0.001

47.96 ± 21.66

65.63 ± 40.28

0.006